SPANX family member CGenealiases: CT11.3 · CTp11 · SPANX-C · SPANX-E · SPANXE
Q-omics provides the consensus-scored SPANXC profile across patient tissues and cancer cell-line models. SPANXC expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPANXC is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, SPANXC RNA expression shows 7,453 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where SPANXC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPANXC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPANXC survival associations across molecular data types. SPANXC RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPANXC RNA expression–survival associations across cancer types. High SPANXC expression shows unfavorable associations in KIRC, KIRP, SCLC, KICH, PAAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPANXC RNA expression.
This table summarizes SPANXC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPANXC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPANXC shows higher tumor expression in HNSC, LUSC and LUAD. The HNSC box plot shows higher SPANXC RNA expression in tumor versus normal tissue (log2 FC = +0.623, t-test p = .001).
This table shows molecular features associated with SPANXC in patient tissues and cancer cell lines. In patient samples, SPANXC shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPANXC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
